论文部分内容阅读
溶栓治疗脑梗塞是近年来研究的热点,是降低脑梗塞致残率的重要手段之一,已取得很好的效果。但其给药的途径、时间、剂量仍在探索之中,这是当今世界各国医学临床需要解决的重要问题。超早期溶栓危险性大,且受时间限制,很难普遍开展。我院对45例超早期后急性脑梗塞病人用小剂量尿激酶和肝素治疗取得了较好效果,现分析如下。 1 临床资料 1.1 一般资料:溶栓组和治疗组各45例,为1999年3月至2000年3月的住院病人,均为超早期后急性脑梗塞病人,发病时间在12小时至5天。年龄46～78岁,平均年龄64.4岁。治疗前查头颅CT示脑梗塞,无脑出血,除外溶栓治疗前临床
Thrombolytic therapy of cerebral infarction is a hot research in recent years, is one of the important means to reduce the rate of disability caused by cerebral infarction, has achieved very good results. However, its route of administration, time and dosage are still being explored, which is an important issue to be solved in clinical medicine in all countries of the world today. Ultra-early thrombolysis risk, and subject to time constraints, it is difficult to carry out universally. 45 cases of ultra-early acute cerebral infarction patients treated with low-dose urokinase and heparin achieved good results, are analyzed as follows. 1 Clinical data 1.1 General information: Thrombolytic group and treatment group of 45 cases, for the March 1999 to March 2000 inpatients, are ultra-early acute cerebral infarction patients, the onset time of 12 hours to 5 days. Age 46 to 78 years old, average age 64.4 years old. Before treatment, check the head CT showed cerebral infarction, no cerebral hemorrhage, except before thrombolytic therapy